Yasuyuki Takahashi
Asahi Kasei
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yasuyuki Takahashi.
Obesity Research & Clinical Practice | 2008
Takashige Sato; Yutaka Nihei; Masakazu Nagafuku; Seiichi Tagami; Rina Chin; Mitsunobu Kawamura; Shigeru Miyazaki; Makoto Suzuki; Shu-ichi Sugahara; Yasuyuki Takahashi; Atsuko Saito; Yasuyuki Igarashi; Jin-ichi Inokuchi
SUMMARY BACKGROUND Insulin resistance is a characteristic feature of metabolic syndrome. Ganglioside GM3 [α-Neu5Ac-(2-3)-β-Gal-(1-4)-β-Glc-(1-1)-ceramide] may impair insulin sensitivity in adipose tissue. We investigated the relationship between serum GM3 levels and adiposity indices, as well as between serum GM3 levels and metabolic risk variables. METHODS Study 1: we assessed serum GM3 levels in normal subjects and in patients with hyperglycemia and/or hyperlipidemia (HL). Study 2: we investigated the relationship between serum GM3 levels and metabolic risk variables in patients with type 2 diabetes. RESULTS Study 1: serum GM3 levels were higher in hyperglycemic patients (1.4-fold), hyperlipidemic patients (1.4-fold) and hyperglycemic patients with hyperlipidemia (1.6-fold), than in normal subjects. Study 2: serum GM3 levels were significantly increased in type 2 diabetic patients with severe obesity (visceral fat area (VFA) >200 cm(2), BMI > 30). The GM3 level was positively correlated with LDL-c (0.403, p = 0.012) in type 2 diabetes mellitus, but not affected by blood pressure. In addition, the high levels of small dense LDL (>10 mg/dL) were associated with the elevation of GM3. CONCLUSIONS Serum GM3 levels was affected by glucose and lipid metabolism abnormalities and by visceral obesity. GM3 may be a useful marker for severity of metabolic syndrome.
Bioscience, Biotechnology, and Biochemistry | 2008
Tomoyuki Miyabayashi; Masashi Yamamoto; Akiko Sato; Seiji Sakano; Yasuyuki Takahashi
Embryonic stem cells (ESCs), which have characteristics such as self-renewal, indefinite proliferation, and pluripotency, are thought to hold great promise for regenerative medicine. ESCs are generally cultured on mouse embryonic fibroblast (MEF) or MEF conditioned medium (MEF-CM). However, for therapeutic applications, it is preferable for ESCs to be cultured under chemically defined conditions. Here, we report synthetic compounds that allow expansion of undifferentiated mouse ESCs in the absence of MEF, Leukemia Inhibitory Factor (LIF), and Fetal Bovine Serum (FBS). ESCs cultured for more than 30 d in a serum-free medium supplemented with indole derivertives retained their characteristic morphology and expressed markers such as SSEA-1, OCT3/4, Rex-1, Sox2, and Nanog. They consistently differentiated into many types of cells, including neurons, muscle cells, and hepatocytes. These results indicate that our compounds provide a more efficient and safer large-scale culture system for pluripotent ESCs, and hence might contribute to the use of ESCs in therapeutic applications.
Archive | 1992
Yasuyuki Takahashi; Akihiro Arai
Archive | 1981
Akio Mimura; Yasuyuki Takahashi; Katsumi Yuasa; Mitsuru Shibukawa
Archive | 1981
Akio Mimura; Yasuyuki Takahashi; Katsumi Yuasa; Mitsuru Shibukawa
Archive | 1981
Akio Mimura; Yasuyuki Takahashi; Katsumi Yuasa; Mitsuru Shibukawa
Archive | 1981
Akio Mimura; Yasuyuki Takahashi; Katsumi Yuasa; Mitsuru Shibukawa
Archive | 1981
Akio Mimura; Yasuyuki Takahashi; Katsumi Yuasa; Mitsuru Shibukawa
Archive | 1981
Akio Mimura; Yasuyuki Takahashi; Katsumi Yuasa; Mitsuru Shibukawa
Archive | 1981
Akio Mimura; Yasuyuki Takahashi; Katsumi Yuasa; Mitsuru Shibukawa